Author:
Kim Su-Hyun,Lee Eun-Jae,Min Ju-Hong,Kim Sung-Min,Shin Ha Young,Kwon Young Nam,Kim Woojun,Oh Jeeyoung,Kim Jun Soon,Baek Seol-Hee,Joo In Soo,Hong Yoon-Ho,Park Min Su,Sohn Eunhee,Nam Tai-Seung,Oh Sun-Young,Huh So-Young,Lee Tae-Kyeong,Yang Jiwon,Kim Sunyoung,Seok Hung Youl,Kim Nam-Hee,Shin Jin-Hong,Bong Jeong Bin,Kwon Soonwook,Oh Seong-il,Cho Eunbin,Shin Hyun-June,Lee Hyung-Soo,Park Kee Hong,Kim Woo Kyung,Bae Jong Seok,Kim Ho Jin
Abstract
Background: In the present era of rapidly evolving treatment options, there is a need for better understanding of the epidemiology and current management of patients with multiple sclerosis (MS). A survey was conducted to determine the epidemiologic characteristics and the current treatment status of patients with MS in Korea.Methods: In April 2022, we collected data on patients with MS, including number participating in follow up, sex ratio, current disease modifying treatment (DMT), and disability status (Expanded Disability Status Score, EDSS) from 30 major MS centers in Korea.Results: A total of 1,290 patients with MS was identified, with a female to male ratio of 2.4:1. Geographically, 1,047 patients (81%) were being monitored at hospitals in the capital regions (Seoul, Incheon, and Gyeonggi-do), while 243 (19%) were receiving care at hospitals outside the capital regions. There were 1,199 patients on DMTs, with 876 (73%) taking drugs with moderate efficacy and 264 (22%) taking drugs with high efficacy. Patients with current EDSS score greater than 3.0 and 5.5 numbered 242 (20%) and 105 (9%), respectively.Conclusion: The hospital-based prevalence survey revealed the number and geographical distribution of patients with MS in Korea.
Publisher
Korean Society of Neuroimmunology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献